Date: 2015-06-17
Type of information: Development agreement
Compound: LY3023414
Company: Eli Lilly (USA - IN) Sarah Cannon Research Institute (SCRI) (USA - CO)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: phosphoinositide 3-kinase (PI3K) inhibitor/mTOR inhibitor. LY3023414 is a selective PI3K/mTOR (phosphoinositide 3-kinase/mammalian target of rapamycin) inhibitor. In vitro, LY3023414 has demonstrated inhibitory activity against PI3K and mTOR in tumor cells, as well as antiproliferative activity and cell cycle effects. In addition, in vitro, LY3023414 inhibits the ability of PI3K and mTOR to phosphorylate substrates in the PI3K/mTOR pathway.
Disease:
Details: * On June 17, 2015, Eli Lilly and Sarah Cannon Research Institute (SCRI) announced a strategic partnership to co-develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway. The partnership supports the development of this novel targeted cancer therapy, including flexible and efficient program design and implementation, as well as more rapid patient enrollment to clinical trials by accessing SCRI\'s large network of patients.
Financial terms:
Latest news:
